4519 N Stock Overview
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Chugai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥567.91 |
| 52 Week High | JP¥567.91 |
| 52 Week Low | JP¥567.91 |
| Beta | 0.50 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -13.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4519 N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | 2.0% | 1.1% |
| 1Y | n/a | -12.4% | 2.5% |
Return vs Industry: Insufficient data to determine how 4519 N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 4519 N performed against the MX Market.
Price Volatility
| 4519 N volatility | |
|---|---|
| 4519 N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 2.1% |
Stable Share Price: 4519 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4519 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 7,771 | Osamu Okuda | www.chugai-pharm.co.jp |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Chugai Pharmaceutical Co., Ltd. Fundamentals Summary
| 4519 N fundamental statistics | |
|---|---|
| Market cap | Mex$762.99b |
| Earnings (TTM) | Mex$41.85b |
| Revenue (TTM) | Mex$160.37b |
18.2x
P/E Ratio4.8x
P/S RatioIs 4519 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4519 N income statement (TTM) | |
|---|---|
| Revenue | JP¥1.21t |
| Cost of Revenue | JP¥513.16b |
| Gross Profit | JP¥698.48b |
| Other Expenses | JP¥382.32b |
| Earnings | JP¥316.15b |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Jul 27, 2023
| Earnings per share (EPS) | 192.18 |
| Gross Margin | 57.65% |
| Net Profit Margin | 26.09% |
| Debt/Equity Ratio | 0% |
How did 4519 N perform over the long term?
See historical performance and comparisonDividends
2.3%
Current Dividend Yield41%
Payout RatioDoes 4519 N pay a reliable dividends?
See 4519 N dividend history and benchmarks| Chugai Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Jun 29 2023 |
| Dividend Pay Date | Aug 30 2023 |
| Days until Ex dividend | 316 days |
| Days until Dividend pay date | 254 days |
Does 4519 N pay a reliable dividends?
See 4519 N dividend history and benchmarks